Being an early stage MedTech or Biopharma Company is a challenging time. With federal funding cuts, entrepreneurs must be resourceful and disciplined to support their strategies and achieve their goals. Mercury's webinar sponsored on Thursday, May 8, will feature early investors in Breyer Capital and MBX Capital, who will discuss alternative funding opportunities available in this uncertain time.
One innovative approach to addressing funding cuts is Artitude Lab Accelerator, launched by Rocursion to support some of the estimated 1,500 health-related startups that have been damaged by Small Business Innovation Research (SBIR) grants. The SBIR grant is a key source of funding for biotechnology innovation and paves the way for life-changing drug development. Prior to layoffs, more than $4 billion in SBIR grants were awarded to early stage companies each year.
The webinar panelists included Morgan Cheatham, director of healthcare and life sciences at Breyer Capital and Gurdane Bhutani, managing partner at MBX Capital. Benjamin Kromnick, who leads healthcare and life sciences at Mercury, will serve as the host. They will share their experiences and discuss how NIH funding cuts affect the overall picture of the life science landscape. They will also receive questions from attendees!
The webinar will also focus on how they can be for startups, what they see in MedTech and biotech development, the technology they are excited about, the role of accelerators, the impact of AI, and their prospects.
To sign up for this webinar, how Fintech makes growth of early life science companies easier with Mercury sponsorship, fill out the following form:
Mercury is a financial technology company, not a bank. Choose banking services provided by financial groups,,,,, List. ,, and Evolution Bank and Trust, Member FDIC.
